• Home
  • Tumor agnostic in Oncology

Tumor agnostic in Oncology

Tumor-agnostic therapies represent a paradigm shift in how we understand and treat cancers


This website comprises scientific information about tumor agnostic approaches in Oncology. 

The genetic etiology of a wide variety of cancers lead to the development of genomically-informed treatment strategies targeting molecular alterations regardless of histological origin. Underlying molecular markers for tumor agnostic in Oncology usually fulfill the following criteria: 

  • Alterations are found across a variety of cancers.

  • Alterations are likely to predict response to a therapy

Within this hub, you will find information about the concept of tumor agnostic in Oncology including recent publications and congress updates.


Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.